Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The MIT Technology Review released its annual report on what technologies are likely to have the biggest impact on the way we ...

Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist.

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.

From groundbreaking immunotherapies to advanced targeted treatments, oncology is set to make historic strides in the year ahead.

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...